샘플 요청 목록에 추가
개요 엑소좀은 엔도솜에서 유래한 세포외 소포(EV)로, 크기는 30-150 나노미터입니다. 거의 모든 유형의 세포에서 분비되는 엑소좀은 세포 특이적인 단백질, 지질, 핵산을 운반하고 수용 세포에 선택적으로 흡수되어 세포 간 소통에 중요한 역할을 합니다.
최근 엑소좀 기술의 발전으로 액체생검, 정밀의료, 재생의료 분야에서 엑소좀의 활용이 확대되고 있습니다. 특히 암 유래 엑소좀은 혈관신생, 전이, 면역을 조절하는 능력으로 가치가 높으며, 암의 발견, 진단, 치료법 선택에 매우 중요합니다.
엑소좀 카고는 암뿐만 아니라 심혈관질환, 신장질환, 신경퇴행성 질환, 대사성 질환 등 다양한 질환의 예후에 대한 지식을 제공합니다. 엑소좀 내에 수많은 생체 분자가 존재한다는 사실이 밝혀지면서 암의 검출, 모니터링, 치료를 위한 암 바이오마커로 활용하기 위한 광범위한 조사가 활발히 진행되고 있습니다.
엑소좀은 혈청, 혈장, 소변, 타액 등 다양한 생체액에 존재하므로 저침습적 진단에 이상적입니다. 또한 예후 지표 및 치료 효과의 예측 인자로도 작용합니다. 또한 엑소좀의 치료적 응용도 연구되고 있습니다. 예를 들어 엑소좀은 결함이나 결손 분자로 인한 질병을 표적 치료하기 위해 치료용 siRNA나 단백질을 운반하도록 설계될 수 있습니다. 간엽줄기세포(MSC) 유래 엑소좀은 염증을 억제하고, 흉터 조직 형성을 방지하며, 면역반응을 조절할 수 있는 가능성을 보여주고 있습니다.
과소평가되었던 엑소좀 분야는 현재 급속도로 발전하고 있습니다. 최근 논문에서 미국 저자와 중국 연구자들의 성과가 두드러지며, 특히 Karolinska Institutet의 Susanne Gabrielsson 박사와 Unicyte AG가 관련 과학 문헌을 주도하고 있습니다.
BioInformant의 세계 전략 보고서는 특허, 보조금, 출판물, 임상시험 동향 등 급성장하는 엑소좀 시장을 자세히 설명합니다. 업계내 제휴, 인수합병(M&A), 자금 조달, 경쟁 구도 및 2030년까지 시장 전망도 함께 다루고 있습니다.
엑소좀을 이용한 진단 및 치료제가 확대되고 있으며, 현재 388건의 임상시험이 진행 중입니다. 엑소좀 치료제는 아직 판매 승인을 받지 못했지만, 2029년까지 첫 5가지 제품이 출시될 것으로 예상됩니다. 엑소좀은 표적에 대한 전달, 부작용 감소, 면역 검출 회피 등 기존 치료법에 비해 유망한 이점을 제공합니다.
엑소좀은 의료용 외에도 피부 회춘, 상처 치유, 흉터 교정, 모발 재생을 촉진하기 위해 화장품에도 사용되고 있습니다. 엑소좀 기반 진단약 2종은 이미 미국 FDA로부터 패스트트랙 승인을 받은 바 있습니다.
이 종합 보고서는 다음과 같은 정보를 제공합니다. :
시장 분석 : 엑소좀 치료제/진단제, 제품/서비스, 제조기술, 화장품 용도
엑소좀 치료제 임상시험 파이프라인(미감작 및 인공 엑소좀 포함)
엑소좀 진단법을 활용한 승인된 제품 및 향후 출시 예정 제품
임상시험 활동: 유형별, 지역별, 상권별, 투자자별, 임상시험 활동
주요 산업 지표 분석 : 과학 논문, 특허, 보조금, 임상시험 등
주요 자금조달 이벤트(M&A, 자금조달 이벤트, 공동개발 계약, IPO 포함)
전략적 파트너십과 경쟁 인사이트사항
시장 규모(시장 부문별, 지역별) 및 예측(-2030년)
업계 동향 및 향후 방향성
이 보고서는 엑소좀 치료제 및 진단, 연구 제품, 제조 기술, 화장품, RTU(Ready-to-Use) 엑소좀을 개발하는 기업에게 시장 정보를 제공하는 것을 목적으로 합니다. 엑소좀 시장에는 많은 경쟁자들이 존재하므로 이 보고서는 많은 시간을 들여 조사하지 않고도 정보를 얻고 기회를 포착할 수 있는 귀중한 리소스를 제공합니다.
목차 제1장 조사 개요
제2장 엑소좀 생물학과 기능 : 개요
엑소좀 구조
엑소좀 분자 함유량
엑소좀 막과 내강 컴포넌트
엑소좀 유래에 의한 분류
합성 엑소좀
세포치료와 유전자 치료의 차이
세포치료로부터 엑소좀 요법으로의 이동
향후 10년간 엑소좀
제3장 엑소좀 엔지니어링 : 새로운 기술 플랫폼
내부 수식
분리전 내부 수식 방법
인큐베이션
유전자 편집
분리 후 내부 수식 방법
표면 개질
친세포에 의한 표면 개질
직접 표면 개질
엑소좀 안 분자 표시
내부 수식
표면·내부 개질 엑소좀
제4장 엑소좀에 관한 과학 간행물
엑소좀 진단법·치료법 출판 동향
주요 기술에 의한 치료용 엑소좀에 관한 PubMed 간행물
PubMed 엑소좀 분리와 정제에 관한 기술 논문
약물 캐리어로서의 지질 나노입자와 엑소좀에 관한 PubMed 논문
엑소좀 간행물 분포 : 질환 유형별
엑소좀 간행물 : 암 유형별
제5장 엑소좀 특허의 개요
엑소좀 특허 공개 추이
엑소좀 특허 : 치료용과 진단용
엑소좀 특허 출원 : 엑소좀 공급원별
특허/특허 출원 : 분리·정제 기술별
특허/특허 출원 : 카고 유형별
특허/특허 출원 : 카고 적재 방법별
특허/특허 출원 : 치료 분야별
엑소좀 특허의 주요 양수인
특허 취득 끝난 분리·조제 기술의 유형 : 양수인별
양수인이 사용하는 카고 유형
카고 적재 방법 : 양수인별
치료 영역 : 양수인별
양수인 카테고리
엑소좀 특허 출원 건수 : 관할 지역별
엑소좀 특허 출원인
엑소좀 특허 발명자
엑소좀 특허 소유자
엑소좀 특허 법적 지위
제6장 엑소좀 : 임상시험의 상황
엑소좀 임상시험 : 연구 단계별
엑소좀 임상시험 : 자금 제공자 유형별
엑소좀 임상시험 : 기술별
엑소좀을 이용한 질환 치료의 임상시험 현황
진단 연구을 위한 엑소좀을 이용한 임상시험
주요 엑소좀 연구개발 기업
전임상 개발중인 엑소좀 치료제
제7장 엑소좀 분리/정제 기술 : 개요
초원심분리(UC)
한외여과(UF)
사이즈 배제 크로마토그래피(SEC)
폴리머 침전법
면역 친화성 포착법
압타머 기반 방법
마이크로 유체 기술
제8장 엑소좀 기업의 독자 기술 플랫폼
선택된 엑소좀 기술 플랫폼 해설
AGLE-102
Hybridosome
AB126
CAP-1002(Deramiocel)
REGENT
ExoFlo
DeliverEX
EXOVEX
ExoSCRT
LEAP
ExoDx
EXPLOR
Exo-Target
제9장 엑소좀 엔지니어링 기술 : 개요
부화법
트랜스펙션법
초음파 처리법
일렉트로포레이션법
압출법
동결 융해법
유전자 엔지니어링적 방법
제10장 엑소좀 치료에 대한 응용 : 개요
엑소좀 치료 분야의 주요 기업
Nano24 EXO-CD24(OBCTCD24)
The Hemopurifier
Carmine Therapeutics REGENT
Ciola 엑소좀 커스터마이즈 기술
Capricor Therapeutics CAP-1002(Deramioce)
ILIAS Biologics EXPLOR
Aruna Bio AB126
Aegle Therapeutics AGLE-102
OmniSpirant Therapeutics OmniSomes
Exogenus Therapeutics EXO-101
RION 정제 엑소좀 제품(PEP)
제11장 엑소좀의 진단에 대한 응용
진단 용도 이점
진단에 중점을 두는 주요 적응증
가장 일반적인 표적 엑소좀 바이오마커
진단 용도 엑소좀 단백질
암 진단약으로서의 엑소좀 miRNA
진단용 엑소좀 연구
엑소좀 진단약의 개발 주요 기업
BioFluidica LiquidScan
ExoCan ExoEnrich
Exosome Diagnostics, Inc.ExoDx 전립선 검사
엑소좀 사이언스 타우솜 검사
Exosomics SpA에 의하지만 진단
Guardant Health Guardant360 CDx
Mursla Bio에 의한 간암 탐지 연구
NanoSomiX BDE 바이오마커 어세이
Theoria Science ExoScreen 어세이
제12장 미용 엑소좀 응용
미용 엑소좀 치료
얼굴 회춘의 엑소좀
육모의 엑소좀
흉터 경감의 엑소좀
유방확대수술의 엑소좀
미용 목적 엑소좀 공급원
피부과학에 관련된 엑소좀 과학
주요 기업과 제품
인기 엑소좀 기반 미용
AnteAGE Pro 시스템
Cartessa ExoCR
ELEVAI Labs ELEVAI enfinity
Exoceuticals EXO PLUS
Kimera Labs Vive
RION Aesthetics CALM Serum
ExoCoBio ASCE Exosomes
제13장 엑소좀 분야 거래와 자금조달
엑소좀 기업에 대한 벤처캐피털 자금
EXO Biologics
Exogenus Therapeutics
INEXOPLAT
Mantra Bio
Anjarium Biosciences
Evox Therapeutics, Ltd.
ILIAS Biologics
ExoCoBio, Inc.
Aegle Therapeutics
Evox Therapeutics
Evox Therapeutics
Codiak BioSciences
Codiak BioSciences
Exosome Diagnostics
Exosome Diagnostics, Inc
EXO 바이오로지크스
엑소좀 분야 파트너십 계약
Cytiva와 Rooster Bio
SomesTech와 ConvEyXO
RoosterBio, Inc.(와)과 FUJIFILM Diosynth Biotechnologies
Evox Therapeutics와 Eli Lilly
Exopharm와 Astellas
Univercells Technologies와 RoosterBio
AgeX Therapeutics와 UCI
VivaZome와 La Trobe University
Evotec SE와 Curexsys GmbH
Bio-Techne와 QIAGEN
InnoCan Pharma와 Recipharms
Codiak BioSciences와 Sarepta
Evox Therapeutics와 Takeda
PureTech와 Roche
Evox Therapeutics와 Boehringer Ingelheim
Sarpeta Therapeutics와 Codiak Biosciences
Navigo Proteins와 MDimune
Jazz Pharmaceuticals와 Codiak BioSciences
Exosome Diagnostics와 Intezyne
Evox Therapeutics와 Boehringer Ingelheim
기업 인수 거래
ExoCoBio와 BENEV
Evox Therapeutics와 Codiak Biosciences' Technology
Lonza와 Exosomics
Lonza와 Codiak Biosciences
Bio-Techne Corporation와 Exosome Diagnostics
Lonza와 HansaBioMed
라이선스 거래
EVerZom와 Erganeo
Elevai Labs와 Yuva Biosciences
TOPPAN와 Dai Nippon Toryo
Carnegie Mellon University(CMU)와 Coya Therapeutics
INOVIQ, Ltd.(와)과 ResearchDx, Inc.
ATUM와 Codiak BioSciences
Johns Hopkins University와 Capricor Therapeutics
Evox Therapeutics와 Eli Lily
Codiak BioSciences와 Sarepta
VivaZome Therapeutics와 University of Adelaide
Evox Therapeutics와 Takeda
CEVEC와 Evox Therapeutics
Orgenesis와 Excella Bio
System Biosciences와 QIAGEN
PureTech Health와 3D Biotechnologies
신규 주식 공개
Elevai Labs
Codiak Biosciences
Codiak Biosciences
Codiak BioSciences
제14장 엑소좀 시장 분석
엑소좀 치료제 시장
세계의 RTU(Ready-to-Use) 정제 엑소좀 시장 : 유형별
엑소좀 진단약 시장
세계의 엑소좀 기술 시장 : 제품 유형별
세계의 엑소좀 기반 미용품(화장품) 시장
엑소좀 시장 전체
엑소좀 요법 시장 촉진요인
제15장 엑소좀 시장의 경쟁사의 개요
101 Bio
Abbexa, Ltd.
AcouSort AB
Aegle Therapeutics
Aethlon Medical, Inc.
Akrivis Health Care Pvt., Ltd.
AM BioTech
AMS Biotechnology, Ltd.(AMSBIO)
AnteAGE
Aposcience AG
Aruna Bio
BENEV Company, Inc.(ExoCoBio)
BioCat GmbH
BioFluidica
Biological Dynamics, Inc.
Biorbyt, Ltd.
Bioscience Institute
Biosynth International, Inc.
BreStem Therapeutics, Inc.
Capricor Therapeutics
Carmine Therapeutics
Cellarcus Biosciences, Inc.
Cell Care Therapeutics
Cells for Cells
Cell Guidance Systems, Ltd.
Ciloa
ConvEyXO
Craif, Inc.
Creative Bioarray
Creative Biostructure
Creative Biolabs
Creative Medical Technology Holdings, Inc.
Creative Proteomics
CUSABIO Technology LLC
Diadem Biotherapeutics
Direct Biologics
Elevai Labs, Inc.
Entelexo Biotherapeutics
EriVan Bio
EVerZom
Evolutionary Biologics, Inc.
Evomic Science LLC
Evox Therapeutics, Ltd.
EXO Biologics
ExoCan Healthcare Technologies Pvt., Ltd.
Exocel Bio
Exogenus Therapeutics
Exokeryx, Inc.
ExoProTher Medical
ExoQure
EXORPHIA, Inc.
ExosomeDx(biotechne)
ExosomePlus
Exosome Sciences
ExoStemTech Co., Ltd.
ExoVectory
ExSURE Pvt. Ltd.
Florica Therapeutics
HansaBioMed Life Sciences, Ltd.
ILIAS Biologics, Inc.
INEXOPLAT, Inc.
Innocan Pharma
Innovex Therapeutics, SL
INOVIQ, Ltd.
Irazu Oncology
Izon Science, Ltd.
Kimera Labs, Inc.
Leading Biology, Inc.
LifeSpan Biosciences, Inc.
Lonza Group, Ltd.
Mantra Bio
Mercury Bio
Mercy Bioanalytics
Micregen, Ltd.
Microgentas
miR Scientific
Liver EV Liquid Biopsy Platform
MyBioSource, Inc.
Nano 24(OBCDCT24)
NanoSomiX, Inc.
Nanovex Biotechnologies
NeurExo Sciences
NeuroDex, Inc.
Norgen Biotek Corporation
Novaxomx GmbH
Novus Biologicals
NurExone Biologic, Inc.
Oasis Diagnostics Corporation
NX Prenatal, Inc.
OmniSpirant Therapeutics
OncoXome, Inc.
Paracrine Therapeutics Pte, Ltd.
QIAGEN
Reactive Medical Labs
ReNeuron
RION Aesthetics, Inc.
Rivela Diagnostics
RoosterBio, Inc.
ShiftBIO
SOL Bio Corporation
SomesTech
Stem Cell Medicine, Ltd.
System Biosciences
Theoria Science, Inc.
TheraXyte
Thermo Fisher Scientific
TheraXyte Bioscience
The Tiny Cargo Company
TransGen Biotech, Co., Ltd.
Tymora Analytical
Unicyte AG
Urvogelbio Pvt, Ltd.
Versatope Therapeutics
VesiCURE Therapeutics
Vesigen Therapeutics, Inc.
VivaZome Therapeutics
ZEO ScientifiX, Inc.
Xosomix
도표 색인 표 색인 KSA
EXECUTIVE SUMMARY Exosomes are extracellular vesicles (EVs) originating from endosomes, with sizes ranging from 30 to 150 nanometers. Secreted by nearly all cell types, exosomes play a key role in cell communication by carrying cell-specific proteins, lipids, and nucleic acids that are selectively absorbed by recipient cells.
Recent advancements in exosome technology are driving growth in their application across liquid biopsy, precision medicine, and regenerative medicine. Cancer-derived exosomes, in particular, are valuable for their ability to regulate angiogenesis, metastasis, and immunity, making them crucial for cancer detection, diagnosis, and treatment selection.
Exosome cargos offer prognostic insights for various diseases, including cardiovascular, renal, neurodegenerative, and metabolic disorders, as well as cancer. The discovery of numerous biomolecules within exosomes has spurred extensive research into their use as cancer biomarkers for detection, monitoring, and treatment.
Exosomes are present in many biofluids such as serum, plasma, urine, and saliva, making them ideal for minimally invasive diagnostics. They also serve as prognostic indicators and predictors of treatment responses. Furthermore, exosomes are being investigated for therapeutic use. For instance, exosomes can be engineered to carry therapeutic siRNA or proteins for targeted treatment of diseases caused by defective or missing molecules. Mesenchymal stem cell (MSC) derived exosomes have shown potential in reducing inflammation, preventing scar tissue formation, and modulating immune responses.
The exosome field, once underappreciated, is now rapidly evolving. Recent publications highlight the significant contributions of U.S. authors and Chinese researchers, with Dr. Susanne Gabrielsson from the Karolinska Institutet and Unicyte AG leading in relevant scientific literature.
BioInformant's global strategic report details the burgeoning exosome market, including trends in patents, grants, publications, and clinical trials. It covers industry partnerships, M&A activities, and financing, with insights into the competitive landscape and market forecasts through 2030.
Exosome-based diagnostics and therapeutics are expanding, with 388 clinical trials currently underway. Although no exosome therapeutics have received marketing approval yet, the first five products are anticipated by 2029. Exosomes offer promising advantages over traditional therapies, including targeted delivery, reduced side effects, and avoidance of immune detection.
In addition to medical applications, exosomes are also being used within cosmetics to promote skin rejuvenation, wound healing, scar revision, and hair restoration. Two exosome-based diagnostics have already received Fast Track approval from the U.S. FDA.
This comprehensive report provides:
Market analysis for exosome therapeutics, diagnostics, product/services, manufacturing technologies, and cosmetic applications
The clinical trial pipeline for exosome therapeutics, including both naive and engineered exosomes
Approved and forthcoming products leveraging exosome diagnostics
Clinical trial activity by type, region, phase, and sponsor
Analysis of key industry metrics, including scientific publications, patents, grants, and clinical trials
Key funding events, including M&A, financing events, co-development agreements, and IPOs
Strategic partnerships and competitive insights
Market size figures, broken down by market segment and geography, with forecasts through 2030
Industry trends and future directions
This report is designed to inform market competitors who are developing exosome therapeutics, diagnostics, research products, manufacturing technologies, cosmeceuticals, and of course, ready-to-use exosomes. With the competitive nature of the exosome market, this report offers a valuable resource to stay informed and seize opportunities, without spending countless hours on research.
TABLE OF CONTENTS 1. REPORT OVERVIEW
1.1. Statement of the Report
1.2. Target Demographic
1.3. Report Sources
1.4. Purpose of the Report
1.5. Executive Summary
1.6. Introduction
2. BIOLOGY & FUNCTIONS OF EXOSOMES: AN OVERVIEW
2.1. Structure of an Exosome
2.1.1. Molecular Contents of Exosomes
2.1.1.1. Proteins in Exosomes
2.1.1.2. Lipid Contents of Exosomes
2.1.1.3. Nucleic Acids in Exosomes
2.1.2. Membrane and Lumen Components of Exosomes
2.1.3. Classification of Exosomes by Origin
2.1.3.1. Natural Exosomes
2.1.3.1.1. Isolation of Natural Exosomes
2.1.3.2. Modified Exosomes
2.1.3.2.1. Types of Therapeutic Cargos Loaded into Exosomes
2.1.3.2.2. Biomedical Applications of Engineered Exosomes
2.1.4. Synthetic Exosomes
2.2. Differences between Cell Therapy and Gene Therapy
2.3. The Shift from Cell Therapy to Exosome Therapy
2.4. Exosomes in the Next Ten Years
3. EXOSOME ENGINEERING: A NEW TECHNOLOGY PLATFORM
3.1. Interior Modification
3.1.1. Pre-Isolation Interior Modification Methods
3.1.2. Incubation
3.1.3. Gene Editing
3.1.4. Post-Isolation Interior Modification Methods
3.2. Surface Modifications
3.2.1. Surface Modification through Parent Cell
3.2.2. Direct Surface Modification
3.2.3. Displayed Molecules in Exosomes
3.3. Interior Modification
3.3.1. Pre-Isolation Interior Modification
3.3.2. Post-Isolation Modification Methods
3.4. An Exosome Showing Modified Surface and Modified Interior
3.4.1. Examples of Hydrophilic Cargo Loaded into Exosome Lumen
4. SCIENTIFIC PUBLICATIONS ON EXOSOMES
4.1. Publication Trends of Exosome Diagnostics and Therapeutics
4.2. PubMed Publications on Therapeutic Exosomes by Loading Technology
4.3. PubMed Papers on Exosome Isolation & Purification by Technology
4.4. PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
4.5. Distribution of Exosome Publications by Disease Type
4.6. Exosome Publications by Cancer Type
5. EXOSOME PATENTS: AN OVERVIEW
5.1. Exosome Patent Publications over Time
5.2. Exosome Patents: Therapeutic vs. Diagnostics
5.3. Exosome Patent Applications by Exosome Source
5.4. Patents/Patent Applications by Isolation/Purification Technologies
5.5. Patents/Patent Applications by Type of Cargo
5.6. Patents/Patent Applications by Cargo Loading Methods
5.7. Patents/Patent Applications by Therapy Area
5.8. Leading Assignees of Exosome Patents
5.8.1. Types of Patented Isolation/Preparations Technologies by Assignees
5.8.2. Types of Cargos Employed by Assignees
5.8.3. Cargo Loading Methods by Assignees
5.8.4. Therapy Areas by Assignees
5.8.5. Assignee Categories
5.9. Exosome Patent Applications by Jurisdiction
5.10. Exosome Patent Applicants
5.11. Exosome Patent Inventors
5.12. Exosome Patent Owners
5.13. Legal Status of Exosome Patents
6. EXOSOMES: CLINICAL TRIAL LANDSCAPE
6.1. Exosome Clinical Trials by Phase of Study
6.2. Exosome Clinical Trials by Funder Type
6.3. Exosome Clinical Trials by Technology
6.4. Current Status of Clinical Trials using Exosomes in Treating Diseases
6.5. Clinical Trials using Exosomes for Diagnostic Studies
6.6. Major Exosome R&D Companies
6.7. Exosome Therapeutics in Preclinical Development
7. EXOSOME ISOLATION/PURIFICATION TECHNOLOGIES: BRIEF OVERVIEW
7.1. Ultracentrifugation (UC)
7.1.1. Differential Ultracentrifugation
7.1.2. Density Gradient Ultracentrifugation (DGU)
7.2. Ultrafiltration (UF)
7.2.1. Tandem-Configured Ultrafiltration
7.2.2. Sequential Ultrafiltration
7.3. Size Exclusion Chromatography (SEC)
7.4. Polymer Precipitation Method
7.5. Immunoaffinity Capture Method
7.6. Aptamer-Based Method
7.7. Microfluidic Technique
8. PROPRIETARY TECHNOLOGY PLATFORMS OF EXOSOME COMPANIES
8.1. Description of Select Exosome Technology Platforms
8.1.1. AGLE-102
8.1.2. Hybridosome
8.1.3. AB126
8.1.4. CAP-1002 (Deramiocel)
8.1.5. REGENT
8.1.6. ExoFlo
8.1.7. DeliverEX
8.1.8. EXOVEX
8.1.9. ExoSCRT
8.1.10. LEAP
8.1.11. ExoDx
8.1.12. EXPLOR
8.1.13. Exo-Target
9. EXOSOME ENGINEERING TECHNOLOGIES: AN OVERVIEW
9.1. Incubation Method
9.2. Transfection Method
9.3. Sonication Method
9.4. Electroporation Method
9.5. Extrusion Method
9.6. Freeze/Thaw Method
9.7. Genetic Engineering Method
10. THERAPEUTIC APPLICATIONS OF EXOSOMES: A BRIEF OVERVIEW
10.1. Key Players in the Exosome Therapeutic Space
10.1.1. EXO-CD24 from Nano24 (OBCTCD24)
10.1.2. The Hemopurifier
10.1.2.1. Hemopurifier in Cancer
10.1.2.2. Hemopurifier in Infectious Diseases
10.1.3. REGENT from Carmine Therapeutics
10.1.4. Exosome Customization Technology from Ciola
10.1.5. CAP-1002 (Deramioce) from Capricor Therapeutics
10.1.6. EXPLOR from ILIAS Biologics
10.1.7. AB126 from Aruna Bio
10.1.8. AGLE-102 from Aegle Therapeutics
10.1.9. OmniSomes from OmniSpirant Therapeutics
10.1.10. EXO-101 from Exogenus Therapeutics
10.1.11. Purified Exosome Product (PEP) from RION
11. DIAGNOSTIC APPLICATIONS OF EXOSOMES
11.1. Advantages in Diagnostic Applications
11.2. Major Indications Focused for Diagnosis
11.3. Most Common Targeted Exosome Biomarkers
11.3.1. Exosomal Proteins for Diagnostic Applications
11.3.2. Exosomal miRNAs as Cancer Diagnostic Agents
11.4. Diagnostic Exosome Research
11.5. Key Players in the Development of Exosome Diagnostics
11.5.1. LiquidScan from BioFluidica
11.5.2. ExoEnrich from ExoCan
11.5.3. ExoDx Prostate Test from Exosome Diagnostics, Inc.
11.5.4. TauSome Test from Exosome Sciences
11.5.5. Cancer Diagnosis from Exosomics S.p.A
11.5.6. Guardant360 CDx from Guardant Health
11.5.7. Liver Cancer Detection study by Mursla Bio
11.5.8. BDE Biomarker Assay from NanoSomiX
11.5.9. ExoScreen Assay from Theoria Science
12. APPLICATIONS OF EXOSOMES IN AESTHETICS
12.1. Aesthetic Exosome Treatments
12.1.1. Exosomes in Facial Rejuvenation
12.1.2. Exosomes in Hair Restoration
12.1.3. Exosomes in Scar Reduction
12.1.4. Exosomes in Breast Augmentation
12.2. Sources of Exosomes for Aesthetic Use
12.3. Science behind Dermatologically Relevant Exosomes
12.4. Key Players & Products
12.5. Popular Exosome-Based Aesthetics
12.5.1. AnteAGE Pro System
12.5.2. ExoCR from Cartessa
12.5.3. ELEVAI enfinity from ELEVAI Labs
12.5.4. EXO PLUS from Exoceuticals
12.5.5. Vive from Kimera Labs
12.5.6. CALM Serum from RION Aesthetics
12.5.7. ASCE Exosomes from ExoCoBio
13. DEALS AND FUNDRAISING IN EXOSOME SPACE
13.1. Venture Capital Funding for Exosome companies
13.1.1. EXO Biologics
13.1.2. Exogenus Therapeutics
13.1.3. INEXOPLAT
13.1.4. Mantra Bio
13.1.5. Anjarium Biosciences
13.1.6. Evox Therapeutics, Ltd.
13.1.7. ILIAS Biologics
13.1.8. ExoCoBio, Inc.
13.1.9. Aegle Therapeutics
13.1.10. Evox Therapeutics
13.1.11. Evox Therapeutics
13.1.12. Codiak BioSciences
13.1.13. Codiak BioSciences
13.1.14. Exosome Diagnostics
13.1.15. Exosome Diagnostics, Inc
13.2. Partnership Deals in Exosome Space
13.2.1. Cytiva & Rooster Bio
13.2.2. SomesTech & ConvEyXO
13.2.3. RoosterBio, Inc. & FUJIFILM Diosynth Biotechnologies
13.2.4. Evox Therapeutics & Eli Lilly
13.2.5. Exopharm & Astellas
13.2.6. Univercells Technologies & RoosterBio
13.2.7. AgeX Therapeutics & UCI
13.2.8. VivaZome & La Trobe University
13.2.9. Evotec SE & Curexsys GmbH
13.2.10. Bio-Techne & QIAGEN
13.2.11. InnoCan Pharma & Recipharms
13.2.12. Codiak BioSciences & Sarepta
13.2.13. Evox Therapeutics & Takeda
13.2.14. PureTech & Roche
13.2.15. Evox Therapeutics & Boehringer Ingelheim
13.2.16. Sarpeta Therapeutics & Codiak Biosciences
13.2.17. Navigo Proteins & MDimune
13.2.18. Jazz Pharmaceuticals & Codiak BioSciences
13.2.19. Exosome Diagnostics & Intezyne
13.2.20. Evox Therapeutics & Boehringer Ingelheim
13.3. Acquisition Deals
13.3.1. ExoCoBio & BENEV
13.3.2. Evox Therapeutics & Codiak Biosciences' Technology
13.3.3. Lonza & Exosomics
13.3.4. Lonza & Codiak Biosciences
13.3.5. Bio-Techne Corporation & Exosome Diagnostics
13.3.6. Lonza & HansaBioMed
13.4. Licensing Deals
13.4.1. EVerZom & Erganeo
13.4.2. Elevai Labs & Yuva Biosciences
13.4.3. TOPPAN & Dai Nippon Toryo
13.4.4. Carnegie Mellon University (CMU) & Coya Therapeutics
13.4.5. INOVIQ, Ltd. & ResearchDx, Inc.
13.4.6. ATUM & Codiak BioSciences
13.4.7. Johns Hopkins University & Capricor Therapeutics
13.4.8. Evox Therapeutics & Eli Lily
13.4.9. Codiak BioSciences & Sarepta
13.4.10. VivaZome Therapeutics & University of Adelaide
13.4.11. Evox Therapeutics & Takeda
13.4.12. CEVEC & Evox Therapeutics
13.4.13. Orgenesis & Excella Bio
13.4.14. System Biosciences & QIAGEN
13.4.15. PureTech Health & 3D Biotechnologies
13.5. IPO
13.5.1. Elevai Labs
13.5.2. Codiak Biosciences
13.5.3. Codiak Biosciences
13.5.4. Codiak BioSciences
14. EXOSOME MARKET ANALYSIS
14.1. Market for Exosome Therapeutics
14.2. The Global Market for Ready-to-Use Purified Exosomes by Type
14.2.1. Market Size of Exosomes by Parent Cell Type
14.3. Market for Exosome Diagnostics
14.4. Global Exosome Technologies Market by Product Type
14.5. Global Exosome-Based Aesthetics (Cosmeceuticals) Market
14.6. The Overall Market for Exosomes
14.7. The Market Driver of Exosome Therapies
15. PROFILES OF EXOSOME MARKET COMPETITORS
15.1. 101 Bio
15.1.1. PureExo Exosome Isolation Kit
15.2. Abbexa, Ltd.
15.3. AcouSort AB
15.3.1. Technology: Acoustic Separation
15.3.2. EIC Award
15.4. Aegle Therapeutics
15.4.1. Research & Development
15.5. Aethlon Medical, Inc.
15.6. Akrivis Health Care Pvt., Ltd.
15.7. AM BioTech
15.7.1. Bio-Pulsed Technology
15.7.2. ExoGiov
15.7.3. LA EXO Exosome Cosmetics
15.8. AMS Biotechnology, Ltd. (AMSBIO)
15.9. AnteAGE
15.9.1. At-Home Skincare Products
15.9.2. At-Home Brow & Lash Products
15.9.3. VRS Box (6 Pack) [$150]
15.9.4. Professional Skincare Products
15.9.5. Growth Factor Microneedling Products
15.9.6. Stem Cell Facial Microchanneling Products
15.9.7. Medical Skin Care Products
15.9.8. Growth Factor Skin Treatment Products
15.9.9. Growth Factor Hair Regeneration Products
15.10. Aposcience AG
15.10.1. Wound Healing
15.10.2. Myocardial Infarction
15.11. Aruna Bio
15.11.1. AB126 (Neural Exosome)
15.12. BENEV Company, Inc. (ExoCoBio)
15.12.1. Exosome Regenerative Complex
15.12.2. Exosome Regenerative Complex +
15.12.3. EXO-XOM Facial
15.13. BioCat GmbH
15.13.1. ExoQuick Exosome Precipitation
15.13.2. Exosome RNA & DNA Purification
15.13.3. Exosome RNA Amplification & Profiling
15.13.4. Exosome Quantification
15.13.5. Exosome Antibody Array
15.13.6. ExoGlow EV Labeling Kits
15.13.7. Exosome Engineering
15.14. BioFluidica
15.14.1. LiquidScan
15.14.2. Exosome Isolation
15.15. Biological Dynamics, Inc.
15.15.1. Verita Technology
15.15.2. ExoVerita Pro Exosome Enrichment Platform
15.15.3. Exosome Isolation & Analysis Services
15.16. Biorbyt, Ltd.
15.17. Bioscience Institute
15.17.1. Bioscience Clinic Middle East
15.17.2. Bioscience Genomics
15.17.3. Services
15.17.3.1. ExoSkin Therapy
15.17.3.2. ExoHair Therapy
15.17.3.3. ExoJoints Therapy
15.17.3.4. ExoMale Therapy
15.17.3.5. ExoFemale Therapy
15.17.3.6. XOLINE Exosome Cosmetics
15.18. Biosynth International, Inc.
15.18.1. ME Kit (Microvesicle Extraction Kit)
15.19. BreStem Therapeutics, Inc.
15.20. Capricor Therapeutics
15.20.1. Portfolio
15.20.2. StealthX Technology
15.21. Carmine Therapeutics
15.22. Cellarcus Biosciences, Inc.
15.22.1. vFC Vesicle Analysis Assays
15.22.2. vTAG Antibodies
15.22.3. Vesicles and Vesicle Assay Standards
15.23. Cell Care Therapeutics
15.24. Cells for Cells
15.24.1. Current Clinical Trial using Exosomes
15.25. Cell Guidance Systems, Ltd.
15.25.1. Exosome Products
15.25.2. Exo-spin Purification
15.25.3. ExoLISA Technology: Exosome Detection
15.25.4. Exosome Validated Antibodies
15.25.5. Instant Exosomes
15.25.6. NTA Size Profiling Service
15.26. Ciloa
15.26.1. Antibodies against Undruggable Targets
15.26.2. Adjuvant & Virus-Free Vaccines
15.26.3. Virus-Free Therapeutic Vectors
15.26.4. Technology
15.27. ConvEyXO
15.27.1. Exo-Harvest Technology
15.27.2. XomeXBio Technology
15.28. Craif, Inc.
15.28.1. NANO IP (Nano Intelligence Platform)
15.29. Creative Bioarray
15.29.1. Exosome Antibodies
15.29.2. Exosome DNA-RNA Extraction Kits
15.29.3. Exosome Isolation Tools
15.29.4. Exosome Standards
15.29.5. Fluorescent Exosome Standards
15.29.6. Liquid Biopsy
15.29.7. Exosome Research Services
15.30. Creative Biostructure
15.30.1. Exosome Products
15.30.2. Exosome Services
15.30.2.1. Exosome Isolation Services
15.30.2.2. Exosome Analysis Services
15.30.2.3. Exosome Characterization Services
15.30.2.4. Exosome Engineering Services
15.30.2.5. Exosome In Vitro Functional Assay
15.30.2.6. Exosome In Vitro Functional Assay
15.31. Creative Biolabs
15.31.1. Exosome Products
15.31.2. Exosome Isolation Tools
15.31.3. Exosome Capture & Quantification Kits
15.31.4. Exosome Antibody Products
15.31.5. Exosome Standards
15.31.6. Exosome Labeling Kits
15.31.7. Exosomes Surface Modification Kits
15.31.8. Exosome Identification Kits
15.31.9. Exosome Marker cDNA Plasmid Products
15.31.10. Exosome Release Modulation Reagents
15.31.11. LipidSync Exosomes
15.31.12. Exosome Services
15.32. Creative Medical Technology Holdings, Inc.
15.32.1. AmnioStem Stroke Therapy
15.33. Creative Proteomics
15.33.1. Exosome Services
15.34. CUSABIO Technology LLC
15.34.1. Exosome Isolation Kits
15.35. Diadem Biotherapeutics
15.36. Direct Biologics
15.36.1. ExoFlo
15.36.2. AmnioWrap
15.37. Elevai Labs, Inc.
15.37.1. ELEVAI enfinity
15.37.2. ELEVAI empower
15.37.3. ELEVAI Root Renewal System
15.38. Entelexo Biotherapeutics
15.39. EriVan Bio
15.39.1. Services
15.39.2. Research Products
15.40. EVerZom
15.40.1. EVerZom Platform
15.41. Evolutionary Biologics, Inc.
15.41.1. EXO ELIXIR
15.41.2. EVO GROW
15.41.3. EVO JEL
15.41.4. EXO RNA
15.41.5. EVO HYBRID
15.41.6. EXO PERIO
15.42. Evomic Science LLC
15.42.1. ExoEZ Exosome Isolation Kit
15.43. Evox Therapeutics, Ltd.
15.43.1. Gene Therapy
15.43.2. Gene Editing
15.43.3. RNA Therapeutics
15.43.4. Precision Therapeutic Targeting
15.43.5. Protein Therapeutics
15.43.6. Manufacturing Exosomes
15.43.7. Focus on Rare Diseases
15.44. EXO Biologics
15.44.1. Lead Product Candidate
15.45. ExoCan Healthcare Technologies Pvt., Ltd.
15.45.1. ExoEnrich
15.45.2. ExoEngineering
15.45.3. SAC-3D
15.45.4. Services
15.45.4.1. Multiphenotype Screen
15.45.4.2. Small Molecule Screening
15.45.4.3. Exo-BiDD
15.46. Exocel Bio
15.46.1. Services
15.46.1.1. Exosome Isolation via Ultracentrifugation
15.46.1.2. Nanoparticle Analysis for Size Distribution and Concentration
15.46.1.3. Custom Experiments with NTA
15.46.1.4. Custom Growth Factors Production
15.46.2. Products
15.46.2.1. Exovex REVIVE
15.46.2.2. Exovex RENEW
15.46.2.3. Exovex REVEAL
15.46.2.4. Exovex REFINE
15.46.2.5. Exovex RESTORE
15.46.2.6. Exovex EQUUSOME
15.46.2.7. Exovex CANISOME
15.46.2.8. Exovex FELISOM
15.47. Exogenus Therapeutics
15.47.1. Exo-101
15.47.2. ExoWound
15.48. Exokeryx, Inc.
15.48.1. Demeter EVPrep
15.48.2. ExoScan
15.49. ExoProTher Medical
15.50. ExoQure
15.50.1. Technology
15.50.2. Products
15.51. EXORPHIA, Inc.
15.51.1. Activation Technology to produce Prime-EV
15.51.2. Modification Technology to Produce Smart-EV
15.51.3. INPACT-EV Technology
15.51.4. EV Analysis Technology: EV-QUEST
15.51.5. EXORPHIA's Product Pipeline
15.52. ExosomeDx (biotechne)
15.52.1. ExoDx Prostate Test
15.52.2. Pharma Services
15.52.3. Biomarker Discovery Services
15.53. ExosomePlus
15.53.1. MSC-Derived Exosomes
15.53.2. ExoCope Technology
15.54. Exosome Sciences
15.54.1. TauSome (Exosomal Tau) Biomarker
15.55. ExoStemTech Co., Ltd.
15.55.1. Cartisome
15.55.2. EST-T-EXO
15.55.3. Hepatosome
15.55.4. Hypoxisome
15.55.5. Exosome Manufacturing Platform
15.55.6. Protein Loading & Delivery Platform
15.56. ExoVectory
15.56.1. Technology
15.56.2. Therapeutic Areas Focused
15.56.3. Exosome Immunotherapy for Cancer
15.56.4. Exosome Gene Therapy
15.57. ExSURE Pvt. Ltd.
15.58. Florica Therapeutics
15.59. HansaBioMed Life Sciences, Ltd.
15.59.1. Products
15.59.2. Services
15.60. ILIAS Biologics, Inc.
15.60.2. Cargo Loading Process
15.60.3. Exo-Target: Platform Technology
15.61. INEXOPLAT, Inc.
15.62. Innocan Pharma
15.62.1. Cannabidiol (CBD)-Loaded Exosomes
15.63. Innovex Therapeutics, SL
15.63.1. Research & Development
15.63.2. Vaccine against Plasmodium vivax malaria (PvRexVac)
15.63.3. Vaccine against COVID-19 (ExoCoVac)
15.63.4. Vaccine against PRRSV (PrrsvExoVac)
15.64. INOVIQ, Ltd.
15.64.1. NETs Technology
15.64.2. EXO-NET Pan Exosome
15.65. Irazu Oncology
15.66. Izon Science, Ltd.
15.66.1. qEV Isolation
15.66.2. qEV Automation
15.66.3. qEV Zenco
15.66.4. Robotic System for Diagnostic Development
15.66.5. qEV Magnetic Concentration Kit
15.66.6. Tunable Resistive Pulse Sensing (TRPS)
15.67. Kimera Labs, Inc.
15.67.1. Vive
15.67.2. Luxir & Luxir+
15.68. Leading Biology, Inc.
15.69. LifeSpan Biosciences, Inc.
15.70. Lonza Group, Ltd.
15.71. Mantra Bio
15.71.1. REVEAL
15.71.2. Partnering
15.72. Mercury Bio
15.72.1. The Chimeric yEV System
15.73. Mercy Bioanalytics
15.73.1. The Mercy Halo Test
15.74. Micregen, Ltd.
15.75. Microgentas
15.75.1. Products
15.75.1.1. Exo TFF
15.75.1.2. ExoFilter
15.75.1.3. ExoCAS-2 (Exosome Clustering and Scattering)
15.75.1.4. ExoPAS Advanced (Exosome Precipitation and Scattering)
15.75.1.5. miRQuick (Exosomal miRNA)
15.75.1.6. PIBEX System
15.75.1.7. Plant Exosomes for Cosmetics
15.75.1.8. Centella Asiatica Extracellular Vesicles (CICA EVs)
15.75.2. Services
15.76. miR Scientific
15.77. Mursla Bio
15.77.1. Liver EV Liquid Biopsy Platform
15.78. MyBioSource, Inc.
15.79. Nano 24 (OBCDCT24)
15.80. NanoSomiX, Inc.
15.81. Nanovex Biotechnologies
15.81.1. Technology
15.81.2. Synthetic Exosomes
15.82. NeurExo Sciences
15.82.1. Research & Development Programs
15.83. NeuroDex, Inc.
15.83.1. ExoSORT
15.83.2. Lumin-EV
15.83.3. Alpha-synuclein Assay
15.83.4. TDP43 Assay
15.83.5. Synaptic Protein Assay
15.83.6. Autophagy Assay
15.83.7. Biomarker Discovery Services
15.83.8. LuminEV Kit
15.84. Norgen Biotek Corporation
15.84.1. Exosome Kits
15.84.1.1. Intact Exosome Purification
15.84.1.2. RNA Isolation from Intact Exosomes
15.84.1.3. Exosome Purification, Exosome RNA and Free-Circulating RNA Isolation
15.84.1.4. RNA Isolation from Purified Intact Exosomes
15.84.1.5. Exosome Depletion
15.84.1.6. Exosome Labeling and Cleaning Kit
15.84.1.7. Isolation Services
15.84.1.8. Contract Manufacturing Services
15.85. Novaxomx GmbH
15.86. Novus Biologicals
15.86.1. Exosome Research Tools
15.87. NurExone Biologic, Inc.
15.88. Oasis Diagnostics Corporation
15.89. NX Prenatal, Inc.
15.90. OmniSpirant Therapeutics
15.90.1. OmniSome Therapeutic Platform
15.91. OncoXome, Inc.
15.91.1. OncoXome's Exosomes
15.92. Paracrine Therapeutics Pte, Ltd.
15.93. QIAGEN
15.93.1. exoEasy Maxi Kit
15.93.2. exoRNeasy Midi Kit
15.93.3. mercury LNA miRNA Focus PCR Panels
15.93.4. miRCURY Exosome Serum/Plasma Kit
15.94. Reactive Medical Labs
15.95. ReNeuron
15.95.1. CustomEX - A Customizable Exosome Platform
15.96. RION Aesthetics, Inc.
15.96.1. Products
15.96.1.1. INTENSE Serum
15.96.1.2. DAILY Serum
15.96.1.3. CALM Serum
15.96.1.4. HAIR Serum
15.97. Rivela Diagnostics
15.98. RoosterBio, Inc.
15.98.1. MSC-derived Exosomes
15.98.2. QuickShip Exosomes
15.98.3. QuickShip MSC and Exosome Media
15.98.4. XF Bioreactor MSC & EV Development Kits
15.98.5. XF Bioreactor MSC & EV Scale-Up Kits
15.98.6. XF Bioreactor MSC & EV Starter Kits
15.98.7. RoosterCollect-EV-CC
15.99. ShiftBIO
15.99.1. NSM Platform Technology
15.100. SOL Bio Corporation
15.100.1. Business Model
15.100.2. NeutraRelease Technology
15.100.3. ExoMain
15.100.4. ExoBead
15.101. SomesTech
15.101.1. Products & Solutions
15.101.1.1. ExoNP
15.101.1.2. ExoLoad
15.101.1.3. AI + DDS
15.102. Stem Cell Medicine, Ltd.
15.103. System Biosciences
15.103.1. Products
15.103.1.1. Exosome Isolation Products
15.103.1.2. Exosome Detection Products
15.103.1.3. Exosome Quantitation Products
15.103.1.4. Exosome Labeling Kit Products
15.103.1.5. Exosome Biomarker Discovery Products
15.103.1.6. Exosome Engineering & Design Products
15.103.2. Services
15.104. Theoria Science, Inc.
15.104.1. ExoScreen Technology
15.105. TheraXyte
15.105.1. TAXY - A Programmable Drug Delivery System
15.106. Thermo Fisher Scientific
15.106.1. Exosome Products for Testing & Research
15.107. TheraXyte Bioscience
15.108. The Tiny Cargo Company
15.109. TransGen Biotech, Co., Ltd.
15.109.1. Products
15.109.1.1. TransExo Cell Media Exosome Kit
15.109.1.2. TransExo Urine Exosome Kit
15.109.1.3. TransExo Serum/Plasma Exosome Kit
15.109.1.4. TransExo Serum/Plasma Exosome Total RNA Extraction Kit
15.109.1.5. TransExo Serum/Plasma Exosome Total miRNA Extraction Kit
15.110. Tymora Analytical
15.110.1. Services
15.110.1.1. Plasma Proteomics (PTMs)
15.110.1.2. Urine Proteomics
15.110.1.3. Saliva Proteomics
15.110.1.4. Tissue Proteomics
15.111. Unicyte AG
15.112. Urvogelbio Pvt, Ltd.
15.113. Versatope Therapeutics
15.113.1. Technology
15.113.2. Universal Influenza Vaccine
15.114. VesiCURE Therapeutics
15.114.1. modEXO Platform
15.114.2. dilEVery Delivery System
15.115. Vesigen Therapeutics, Inc.
15.115.1. ARMMs
15.115.2. Disease Areas of Focus
15.115.2.1. Ocular
15.115.2.2. Immunology
15.115.2.3. Neurology
15.115.2.4. Hematology
15.116. VivaZome Therapeutics
15.116.1. VivaZome's Clinical Targets
15.117. ZEO ScientifiX, Inc.
15.117.1. Aesthetic Exosomes
15.117.2. PPX
15.118. Xosomix
INDEX OF FIGURE
FIGURE 2.1: Classification of Extracellular Vesicles
FIGURE 2.2: Exosome Formation
FIGURE 2.3: Exosome Uptake by Target Cells
FIGURE 2.4: Structure of an Exosome
FIGURE 2.5: Membrane Lumen Components of Exosomes
FIGURE 2.6: Classification of Exosomes by Origin
FIGURE 2.7: Exosome Isolation Methods
FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display
FIGURE 3.1: Pre-Isolation Interior Modification Methods
FIGURE 3.2: Post-Isolation Interior Modification Methods
FIGURE 3.3: Surface Modification through Parent Cell
FIGURE 3.4: Direct Surface Modification
FIGURE 3.5: Pre-Isolation Interior Modification Methods
FIGURE 3.6: Post-Isolation Interior Modification Methods
FIGURE 3.7: An Engineered Exosome showing Surface and Interior Modifications
FIGURE 4.1: Number of PubMed.gov Publications, 2000-2024
FIGURE 4.2: Publication Trends of Exosome Diagnostics and Therapeutics
FIGURE 4.3: Number of PubMed Papers on Exosome Cargo-Loading by Technology
FIGURE 4.4: PubMed Papers on Exosome Isolation & Purification by Technology
FIGURE 4.5: PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
FIGURE 4.6: Distribution of Exosome Publications by Disease Type
FIGURE 4.7: Exosome Publications by Cancer Type
FIGURE 5.1: Exosome Patent Publications over Time, 2000-June 2024
FIGURE 5.2: Exosome Patents: Therapeutic vs. Diagnostics
FIGURE 5.3: Exosome Patents/Patent Applications by Exosome Sources
FIGURE 5.4: Patents/Patent Applications by Isolation-Preparation Technologies
FIGURE 5.5: Patents/Patent Applications by Type of Cargo
FIGURE 5.6: Patents/Patent Applications by Cargo Loading Methods
FIGURE 5.7: Patents/Patent Applications by Therapy Area
FIGURE 5.8: Leading Assignees of Exosome Patents
FIGURE 5.9: Top Five Countries with Exosome Patents
FIGURE 6.1: Percent Share of Clinical Trials by Application
FIGURE 7.1: Schematic of Differential Ultracentrifugation
FIGURE 7.2: Schematic of Density Gradient Ultracentrifugation
FIGURE 7.3: Schematic of Tandem Configured Ultrafiltration
FIGURE 7.4: Sequential Ultrafiltration
FIGURE 7.5: Schematic of Size Exclusion Chromatography
FIGURE 7.6: Schematic of Polymer Precipitation Method
FIGURE 7.7: Schematic of Immunoaffinity Capture Method
FIGURE 7.8: Diagram of Working Principle of Microfluidic Device
FIGURE 9.1: Schematic of Incubation Method of Drug Loading
FIGURE 9.2: Schematic of Transfection Method
FIGURE 9.3: Schematic Illustration of Sonication Method
FIGURE 9.4: Schematic Illustration of the Principle of Electroporation
FIGURE 9.5: Schematic Illustration of Drug Loading by Extrusion Method
FIGURE 9.6: Schematic Illustration of Genetic Modification of Exosome
FIGURE 10.1: Schematic Illustration of the Structure of EXO-CD24
FIGURE 10.2: Aethlon's Hemopurifier
FIGURE 10.3: Ciola's Unique in vivo Technology
FIGURE 10.4: Schematic of EXPLOR
FIGURE 10.5: CNS Specificity of AB126
FIGURE 10.6: OmniSomes from OmniSpirant
FIGURE 10.7: EXO-101 from Exogenus
FIGURE 11.1: Great Things in Tiny Packages
FIGURE 11.2: Major Indications Focused for Diagnosis
FIGURE 11.3: LiquidScan from BioFluidica
FIGURE 11.4: Exosome Isolation by ExoEnrich
FIGURE 11.5: Features of ExoDx Prostate Test
FIGURE 11.6: ExoScreen Assay from Theoria Science
FIGURE 12.1: Exosomes in Facial Rejuvenation using DermaPen
FIGURE 12.2: Exosome Therapy for Hair Restoration
FIGURE 12.3: Exosomes in Scar Reuction
FIGURE 12.4: AnteAGE Pro System
FIGURE 12.5: ExoCR from Cartessa
FIGURE 12.6: ELEVAI enfinity
FIGURE 12.7: EXO PLUS from Exoceuticals
FIGURE 12.8: Vive from Kimera Labs
FIGURE 12.9: CALM Serum from RION Aesthetics
FIGURE 12.10: ASCE Exosomes from ExoCoBio
FIGURE 14.1: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
FIGURE 14.2: Global Market for Ready-to-Use Exosomes by Type, 2023
FIGURE 14.3: Global Exosome Therapy Market by Parent Cell Type, 2023
FIGURE 14.4: Global Market for Exosome Diagnostics by Geography, 2023-2031
FIGURE 14.5: Global Exosome Technologies Market by Products, 2023-2031
FIGURE 14.6: Global Market for Exosome-based Aesthetic Products by Segment
FIGURE 14.7: The Overall Exosome Market by Segment, 2031
FIGURE 15.1: Aethlon's Hemopurifier
FIGURE 15.2: qEV Zenco for Therapeutic Development
FIGURE 15.3: Robotic System for Diagnostic Development
INDEX OF TABLES
TABLE 2.1: Number of Molecular Contents identified in Exosomes
TABLE 2.2: Proteins Identified in Exosomes
TABLE 2.3: Common Lipid Contents of Exosomes
TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes
TABLE 2.5: Types of Therapeutic Cargos Loaded into Exosomes
TABLE 2.6: Differences between Cell Therapy and Exosome Therapy
TABLE 3.1: Hydrophobic Cargo Incorporated in Exosome Mmbrane
TABLE 3.2: Examples of Hydrophilic Cargo Loaded into Exosome Lumen
TABLE 5.1: Exosome Patent Applications by Jurisdiction as of June 23, 2024
TABLE 5.2: Exosome Patent Applicants
TABLE 5.3: Exosome Patent Inventors
TABLE 5.4: Exosome Patent Owners
TABLE 5.5: Legal Status of Exosome Patents as of June 22, 2024
TABLE 6.1: Exosome Clinical Trials by Phase of Study
TABLE 6.2: Exosome Clinical Trials by Funder Type
TABLE 6.3: Exosome Clinical Trials by Technology
TABLE 6.4: Current Status of Clinical Trials using Exosomes in Treating Diseases
TABLE 6.5: Clinical Trials using Exosomes for Diagnostic Studies
TABLE 6.6: Major Exosome R&D Companies
TABLE 6.7: Exosome Therapeutics in Preclinical Development
TABLE 8.1: Exosome Technology Platforms Developed by Commercial Companies
TABLE 10.1: Key Players in Therapeutic Exosome Research
TABLE 11.1: Most Common Targeted Exosome Biomarkers
TABLE 11.2: Exosomal Proteins for Diagnostic Applications
TABLE 11.3: Exosomal miRNAs as Cancer Diagnostic Agents
TABLE 11.4: A Sample of Exosome Diagnostic Clinical Trials
TABLE 11.5: Key Players in the Development of Exosome Diagnostics
TABLE 12.1: Key Players in Exosome-based Aesthetics
TABLE 13.1: Venture Capital Funding raised by Exosome Companies
TABLE 13.2: Partnership/Collaboration Deals in Exosome Space
TABLE 13.3: Acquisition Deals in Exosome Space
TABLE 13.4: Licensing Deals in Exosome Space
TABLE 13.5: Exosome Companies raising IPO Funds
TABLE 14.1: Likely-to-be Approved Exosome Therapeutics between 2026 and 2029
TABLE 14.2: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
TABLE 14.3: Global Market for Ready-to-Use Exosomes by Type, 2023-2031
TABLE 14.4: Global Exosome Therapy Market by Parent Cell Type, 2023-2031
TABLE 14.5: Global Market for Exosome Diagnostics by Geography, 2023-2031
TABLE 14.6: Global Exosome Technologies Market by Products, 2023-2031
TABLE 14.7: Global Market for Exosome-based Aesthetic Products by Segment
TABLE 14.8: The Overall Market for Exosomes
TABLE 15.1: Aegle's Product Pipeline
TABLE 15.2: Aruna Bio's Product Pipeline
TABLE 15.3: BreStem Therapeutics' Product Pipeline
TABLE 15.4: Capricor's Multi-Stage Pipeline
TABLE 15.5: Entelexo's Pipeline
TABLE 15.6: Evox Therapeutics' Product Pipeline
TABLE 15.7: EXO Biologic's Product Pipeline
TABLE 15.8: EXORPHIA's Product Pipeline
TABLE 15.9: ExoStemTech's Pipeline Products
TABLE 15.10: ILIAS' Product Pipeline
TABLE 15.11: INOVIQ's Development Pipeline
TABLE 15.12: NeurExo's Research & Development Programs
TABLE 15.13: NeuroDex's Pipeline
TABLE 15.14: ShiftBIO's Natural Drug Delivery Platform-based Programs
TABLE 15.15: Unicyte's Pipeline
